QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 inogen-raises-fy2025-sales-guidance-from-352000m-355000m-to-354000m-357000m-vs-353700m-est

Inogen (NASDAQ:INGN) raises FY2025 sales outlook from $352.000 million-$355.000 million to $354.000 million-$357.000 million vs...

 inogen-sees-q3-sales-91000m-93000m-vs-93267m-est

Inogen (NASDAQ:INGN) sees Q3 sales of $91.000 million-$93.000 million vs $93.267 million analyst estimate.

 b-riley-securities-initiates-coverage-on-inogen-with-buy-rating-announces-price-target-of-14

B. Riley Securities analyst Anderson Schock initiates coverage on Inogen (NASDAQ:INGN) with a Buy rating and announces Price...

 inogen-upgraded-analyst-sees-growth-ebitda-breakthrough

Needham's Mike Matson upgrades Inogen to Buy, citing turnaround progress, margin gains, and path to EBITDA breakeven by 2025.

 needham-upgrades-inogen-to-buy-announces-12-price-target

Needham analyst Mike Matson upgrades Inogen (NASDAQ:INGN) from Hold to Buy and announces $12 price target.

 stifel-maintains-hold-on-inogen-lowers-price-target-to-7

Stifel analyst Mathew Blackman maintains Inogen (NASDAQ:INGN) with a Hold and lowers the price target from $10 to $7.

 inogen-sees-q2-sales-89000m-91000m-vs-9273m-est

Inogen (NASDAQ:INGN) sees Q2 sales of $89.000 million-$91.000 million vs $92.73 million analyst estimate.

 inogen-affirms-fy2025-sales-guidance-of-35200m-35500m-vs-35281m-est

Inogen (NASDAQ:INGN) affirms FY2025 sales outlook from $352.00 million-$355.00 million to $352.00 million-$355.00 million vs $3...

 inogen-q1-adj-eps-011-beats-050-estimate-sales-8228m-beat-7955m-estimate

Inogen (NASDAQ:INGN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.50) by 78 ...

 needham-reiterates-hold-on-inogento-hold

Needham analyst Mike Matson reiterates Inogen (NASDAQ:INGN) from Hold to Hold.

 needham-reiterates-hold-on-inogento-hold

Needham analyst Mike Matson reiterates Inogen (NASDAQ:INGN) from Hold to Hold.

 whats-going-on-with-medtech-focused-inogen-stock-on-wednesday

Inogen beat Q4 earnings and revenue estimates, citing strong B2B demand. Analysts see potential but flag supply challenges and ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION